U.S., Sept. 6 -- ClinicalTrials.gov registry received information related to the study (NCT07156539) titled 'A Phase 3 Study of HS-20094 in Patients With T2DM' on Aug. 28.
Brief Summary: The study is being conducted to evaluate the efficacy and safety of HS-20094 once weekly (QW) in subjects with type 2 diabetes mellitus not adequately controlled with metformin monotherapy or in combination with SGLT2 inhibitors compared to Dulaglutide QW for 44 weeks and 52 weeks.
Study Start Date: Sept. 30
Study Type: INTERVENTIONAL
Condition:
Type 2 Diabetes
Intervention:
DRUG: HS-20094 Injection
HS-20094 injected subcutaneously once weekly
DRUG: Dulaglutide Injection
Dulaglutide injected subcutaneously once weekly
Recruitment Status: NOT_YET_...